Back to Search

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

  • Protocol Number: 201709055
  • Principal Investigator: Johanns, Tanner
  • Cancer Types: Neurological

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Protocol Interventions

Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment